LB Pharmaceuticals Inc (LBRX)
NGM · Healthcare · Biotechnology
$28.42
-0.42%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$815.0M
Shares Outstanding
28.7M
Exchange
NGM
Currency
USD
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -4.9M | -5.2M | -13.9M | -22.1M |
| Net Income | -4.9M | -3.6M | -11.5M | -19.1M |
| Diluted EPS | $nan | $-0.61 | $-0.45 | $-0.67 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.8M | -11.4M | -64.8M | -30.4M |
| Net Income | -14.3M | -6.3M | -63.1M | -25.2M |
| Diluted EPS | $-4.05 | $-1.77 | $-17.82 | $-3.13 |